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Abstract
Background—Most Alzheimer's disease clinical trials that compare the use of health services 
rely on reports of caregivers. The goal of this study was to assess the accuracy of self-reports 
among older adults with Alzheimer's disease and their caregiver proxy respondents. This issue is 
particularly relevance to Alzheimer's disease clinical trials because inaccuracy can lead both to 
loss of power and increased bias in study outcomes.
Methods—We compared respondent accuracy in reporting any use and in reporting the 
frequency of use with actual utilization data as documented in a comprehensive database. We next 
simulated the impact of under-reporting and over-reporting on sample size estimates and treatment 
effect bias for clinical trials comparing utilization between experimental groups.
Results—Respondents self-reports have a poor level of accuracy with Kappa values often below 
0.5. Respondents tend to under-report use even for rare events such as hospitalizations and nursing 
home stays. In analyses simulating under- and over-reporting of varying magnitude, we found that 
errors in self-reports can increase the required sample size by 15–30%. In addition, bias in the 
reported treatment effect ranged from 3%–18% due to both under-reporting and over-reporting 
errors.
Conclusions—Use of self-report data in clinical trials of Alzheimer's disease treatments may 
inflate sample size needs. . Even when adequate power is achieved by increasing sample size, 
reporting errors can result in a biased estimate of the true effect size of the intervention.
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INTRODUCTION
Clinical trials investigating the effectiveness of new treatments for Alzheimer's disease may 
report outcomes across multiple domains including outcomes relevant to the patient, the 
caregiver, and the health care system.1–7 In the typical framework explaining the 
relationship between these outcomes, scientists might hypothesize that an intervention 
improves patient cognition or behavior which then leads to improved patient quality of life 
and reduced caregiver stress and these improvements thereby lead to decreased health care 
use.8–10 Among older adults with Alzheimer's disease, reducing health care cost is an 
important target because older adults with dementia accrue much higher health care costs 
that those without dementia.11–13 Delaying time to institutionalization has been a 
particularly high-value goal because this is an important outcome for patients, caregivers, 
and third-party payers.8,9,14 Indeed, nursing home care is so expensive that treatments that 
might be considered otherwise too expensive can be justified if they are able to demonstrate 
savings in the cost of nursing facility care.8,15–17
Resource use surveys have been developed for use in general population studies and also for 
use among older adults with dementia.18–20 These instruments query respondents and their 
caregivers about the frequency of episodes of care, lengths of stay for hospitalizations or 
nursing facility care, and may also seek to identify specific dates, for example, of 
institutionalization. Some of these surveys also seek to quantify the cost of unpaid 
caregiving. Most Alzheimer's disease clinical trials that measure the use of health services 
rely on surveys of caregiver's self-reports of patient's use of health services.3,18,21–23 The 
“proxy self-reports” of health care use can be converted to estimates of total health care 
costs by assigning an average monetary value to each episode of care, such as the average 
cost of a Medicare hospital stay.
Self-reports of health service use are known to have substantial error.24–28 Respondent 
errors may be due to recall bias, telescoping (recall of events correctly but not in the correct 
time frame), or perceptions of social acceptability.28 The potential bias introduced by 
systematic and non-systematic error in self-reported health care use varies based on the 
study population, hypothesis, and design.28 We previously conducted a randomized 
controlled clinical trial of collaborative care for older adults with Alzheimer's disease.29 As 
part of this clinical trial, we collected data on resource use from subjects' caregivers using 
the Resource Use Inventory.30 We also obtained utilization data from the local electronic 
medical record to supplement the self-reported data in the original clinical trial. More 
recently, we obtained subjects' actual Medicare and Medicaid claims data as well as their 
standardized nursing home and home health care assessments. The specific aim of this study 
was to assess the accuracy of self-reports of health care use among older adults with 
Alzheimer's disease and their caregiver proxy respondents. We then use these findings to 
simulate the impact of errors in self-reports on sample size and power considerations in 
clinical trials of Alzheimer's disease seeking to demonstrate difference in health care use 
between experimental groups. We pursued these simulations because most Alzheimer's 
disease clinical trials are small (<200 subjects) and yet the consumers of these studies often 
demand cost-effectiveness evidence which is most often derived through data on self-
reported utilization. Thus, error within these self-reports could results in study conclusions 
Callahan et al. Page 2
Alzheimer Dis Assoc Disord. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
that show no effect of the intervention on utilization when one actually exists (due to 
inadequate statistical power). Even in the setting of adequate power, the study could report 
an effect of the intervention that was biased (an effect size that is erroneously too high or too 
low) due to errors from self-reports.
METHODS
This study was approved by the Indiana University Purdue University- Indianapolis 
Institutional Review Board and the Centers for Medicare and Medicaid Services Privacy 
Board. The current report focuses on the 100 subjects enrolled from an urban safety net 
health system serving the Indianapolis area and randomized to intervention or control 
groups.29 Because the study intervention did not alter capacity for self-reported health care 
use, we report the results of these 100 subjects in aggregate. All subjects enrolled in the 
original trial were enrolled as dyads so that all subjects with Alzheimer's disease were 
enrolled with an informal caregiver. The original clinical trial was powered to demonstrate 
clinically significant differences in the Neuropsychiatric Inventory and was not powered to 
demonstrate differences in health care use between experimental groups.
Data from this study come from two sources: (1) self-reported utilization data as reported by 
the caregiver and collected in the prior clinical trial; and (2) actual utilization data as 
documented in medical records and claims data for the same period covered by the self-
reported utilization data.11 The clinical trial used the Alzheimer's Disease Cooperative 
Studies Group Resource Use Inventory.19,30 This instrument was delivered by professional 
research assistants in telephone interviews at baseline (covering the 6 months prior to 
baseline), 6, 12, and 18 months. The Resource Use Inventory includes questions about 
assistive devices, examinations by doctors or nurses, use of adult day care, and hours of non-
professional caregiving. For the purposes of this project we focused on the four items below:
• In the last six months, how many different visits has [subject] had to a hospital 
emergency room or urgent care facility
• In the last six months, how many times was [subject] admitted to the hospital?
• In the last six months, how many nights did [subject] spend in the nursing home?
• In the last 6 months, how many days did a home health aide, attendant or any other 
paid individual look after [subject]?
We focused on these four outcomes because they represent the high cost health care 
utilization patterns of concern to third-party payers and the utilization patterns that 
Alzheimer's disease interventions seek to decrease. Actual utilization data were documented 
in a unique dataset in which we merged the clinical data available from a regional health 
information exchange31 with four additional databases: (1) Medicare claims; (2) Resident 
Level Minimum Data Set (MDS); (3) Outcome and Assessment Information Set; (OASIS) 
and (4) Indiana Medicaid claims. Through this comprehensive database, we can document 
health care use across health care systems and across the continuum of care. Thus, the data 
on utilization are not limited to data collected at a single health care system or a single 
payor. Episodes of care within this database include documentation of actual dates of use so 
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we can place use within the baseline (−6 months to 0 months), 6 (0–6 months, 12 (7–12 
months), and 18 (13–18 months) month windows used in the self-report data. Alternatively, 
total use over the entire time period can be summed from self-report or claims data. For each 
patient, we determined all emergency department use, all hospitalizations, all nursing 
facility use, and all home health use for each of the time periods corresponding to the self-
report survey. We used data available in any of the merged datasets to capture any of these 
episodes of care including MDS and OASIS data.
For each subject, we compared the self-reported data for use in any of the four care sites 
(emergency department, hospital, nursing home care, or home health care) first by looking at 
agreement on whether any use occurred. We report kappa statistics for each 6 month period 
for each of the four sites of care using any use as the comparison unit. This requires the 
respondent only to correctly report if use in the site occurred in the past six months as a yes 
or no question. We also report the percentage of patients who over-estimated or under-
estimated use. To explore respondents' accuracy on the volume of use, we examined 
agreement on the volume of use (number of emergency department visits, number of 
hospitalizations, number of nights in the nursing home, and number of days of home health 
care).
Using data from the prior clinical trial, we designed a simulation to demonstrate the impact 
of various rates of under- and over-reporting of health care use on the estimated power for 
an equal sized two group comparison study. In the simulation, we assumed that a generic 
self-reported care utilization count for the ith subject followed a negative binomial 
distribution with mean (i.e., annual rate) of λi, and variance λi +k λi2, where k was the 
dispersion parameter indicating the level of data dispersion. Of note, power calculations on 
utilization counts in most clinical trials are based on a Poisson data assumption. The 
negative binomial distribution is a more general family of distributions that includes the 
Poisson distribution as a special case: when k=0, Yi~Poisson(λi). Under the standard 
formulation of log linear regression models, we expressed the subject-specific care 
utilization rate as λi=exp(β0+β1·Groupi+β2·Underi+β3·Overi) where β0 was the 
logarithmically transformed overall annual rate of utilization; Groupi was the treatment 
indicator for the ith subject (Groupi=1 if the subject had received the intervention and 
Groupi=0 if the subject had received usual care), and β1 was the average treatment effect; 
Underi was an indicator for utilization under-reporting (Underi=1 indicated the utilization 
count was under-reported, and Underi=0 if utilization was not under-reported), and β2 
represented the magnitude of under-reporting; similarly, Overi was an indicator for over-
reporting (Overi=1 if utilization was over-reported), and β3 represented the magnitude of 
over-reporting. In the simulation, we set β0=loge(1)=0 (on average one utilization event per 
year), β1=loge(0.8) (i.e., 20% reduction in utilization rate in intervention group), and for β2 
we considered two different values: β2 = loge(0.7) and β2 = loge(0.5) (i.e., 30% and 50% 
reduction in those who under-reported their utilization counts); for β3 we used β3 = 
−loge(0.7) (i.e., 30% inflation in utilization counts in those who over-reported their 
utilization counts). We considered scenarios where sample size per treatment arm ranged 
from 150 to 900 at 150 increment; for a given sample size, we assumed that 1/3 of the 
subjects who had reported utilization correctly, whereas 1/6, 1/3, or ½ of the subjects had 
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either over-reported or under-reported their care utilization. Using count data generated from 
the negative binomial model, we compared the simulated power to the situation of no 
biased-reporting. For each parameter setting, we generated 20,000 data sets. The simulated 
power corresponding to each sample size was presented graphically.
RESULTS
Table 1 describes the clinical characteristics of the 100 subjects. In general, these subjects 
are similar to those in typical Alzheimer's disease clinical trials as measured by age, gender, 
and cognitive function. However, these subjects also suffer from a significant number of 
comorbid conditions consistent with the original trial's goal to enroll a sample representative 
of patients with dementia in primary care. Table 2 shows the agreement between actual use 
and self-reported use when respondents are only required to correctly reported “any use” as 
compared to “no use”. In this table, the cumulative reporting period increases by 6 months 
across each column. In general, across the four sites of care, respondents tended to under-
report use. Even in the setting of rare but hypothetically notable events, such as nursing 
facility use, there was under-reporting. Table 3 again shows the agreement between actual 
use and self-reported use when respondents are only required to correctly reported “any use” 
as compared to “no use”. As compared to Table 2, in Table 3 the reporting period is for each 
6 month reporting period. In both Tables 2 and 3, kappa statistics are generally poor. Table 4 
shows agreement between self-reports of volume of use and actual volume of use for the first 
six month reporting period and the first and second six month reporting periods combined 
(12 month aggregate). Notably, a large percentage of subjects have no utilization in these 
sites of care and levels of agreement in volume are driven largely by the number of 
respondents correctly reporting “zero use”. Despite the high likelihood of zero use, 
agreement as measured by the Kappa statistic is poor across all four sites of care.
We then conducted a simulation study to determine the impact of under- and over-reporting 
on the statistical power of a hypothetical clinical trial of a novel Alzheimer disease 
intervention seeking to reduce health care costs. We also describe the potential for bias in 
outcome findings. Herein, we generated count data where intervention subjects had a 20% 
reduction in utilization rate as compared to control subjects and we contend that a difference 
of such magnitude would constitute a clinically meaningful and economically important 
reduction in use. Count data in this scenario could be either hospitalizations or nursing home 
stays. Although many clinical trials are powered to demonstrate clinically important 
differences in continuous outcomes such as cognition or behavioral symptoms, we focused 
specifically on the power implications of amnestic under-reporting on these high-cost 
utilization outcomes. We considered scenarios of varying proportions of subjects under- and 
over-reporting their care use as well as the magnitude of under-reporting. In each figure, we 
report the impact of this error based on proportions of respondents in different scenarios: (1) 
1/3 no bias (no errors), 1/3 under-report, 1/3 over-report, (2) 1/3 no bias, ½ under-report, 1/6 
over-report, and (3) 1/3 no bias, 1/6 under-report and ½ over-report. In Figure 1 the 
magnitude of under-reporting is 30% and in Figure 2 it is 50% (Figure 2) lower than the 
actual rate of care utilization. In both figures, the magnitude of over-reporting is 30%.
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In the absence of self-reporting bias in both Figures 1 and 2, the hypothetical study seeking 
to demonstrate a 20% reduction in counts of hospitalizations or nursing home stays at 80% 
power would require approximately 525 subjects per group for a total sample size of 1050. 
In Figure 1, with 50% of subjects under-reporting events by 30% and 1/6 over-reporting the 
events by 30%, the required sample size to maintain a power of 80% would grow to 
approximately 600 subjects per group or a total sample size of 1200 subjects. In Figure 2, 
with 50% of subjects under-reporting events by 50% and 1/6 over-reporting events by 30%, 
the required sample size to maintain a power of 80% would grow to approximately 675 
subjects per group or a total sample size of 1350 subjects. Although not shown in the 
Figures, multiple other factors would also inflate the estimated sample size. For example, we 
assumed that the bias in self reports was not differential between the experimental groups 
but we note that a differential bias in reporting would further inflate the estimated sample 
size. The current simulation assumed a negative binomial distribution in the count variables 
and did not consider the possibility of an excessive number of zero events. If the analysis 
considered the likely inflation of zero events in the distribution of events such as 
hospitalizations or nursing home stays, this would also inflate the estimated sample size.
While the simulation above focuses on the power and sample size implications of biased 
patient self-reports, over-reporting of care utilization also biases the estimation of treatment 
effect. In other words, patient over-reporting of care utilization affects not only the power of 
the test but also the estimation of the treatment effect. Figure 1 focuses on the power 
consequences of over and under-reporting. When a significant number of the study subjects 
over-report their utilization, the analytical power appears to be inflated (improved). But this 
power inflation comes at the expense of increased bias in treatment effect estimation. Thus, 
bias in self-reporting translates into bias in the estimated effect size.
Except for the no bias reporting scenario, all settings with under or over reporting also 
resulted in biased treatment effect estimates. In the scenario where 1/3 had no bias, 1/3 had 
under reporting and 1/3 had over reporting, the magnitude of the average bias was 4.5% of 
the true treatment effect. In the scenario where 1/3 had no bias, 1/2 had under reporting and 
1/6 had over reporting, the magnitude of the average bias was 8% of the true treatment 
effect. In the scenario where 1/3 had no bias, 1/6 had under reporting and 1/2 had over 
reporting, the magnitude of the average bias was 17% of the true treatment effect. Notably, 
the scenario where 1/3 of patients had no reporting bias, 1/6 had under reporting and ½ had 
over reporting (which appeared to have the best power) actually had the worst level of bias 
in treatment effect estimate. In other words, the power inflation resulting from misreporting 
was achieved at the expense of substantially increased treatment effect bias. For Figure 2, 
the corresponding average treatment effect bias is 3%, 18%, and 13%.
DISCUSSION
Self-reports of health care use and hours spent in caregiving have been used to estimate the 
total cost of care for older adult with Alzheimer's disease.5,8,12,13,32 These reports 
consistently demonstrate higher costs of care for these patients relative to older adults 
without dementia. These self-reports also demonstrate the substantial cost of informal 
caregiving in the home as well as the cost of professional caregiving in the home or the 
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nursing home. In these prior studies, respondents typically report events such as 
hospitalizations or hours spent in caregiving over a fixed time interval such as 6 months or 1 
year. These events are then translated into costs based on market estimates or other metrics 
relevant to the particular study and depending on the research team's decisions on assuming 
a societal perspective versus another economic perspective. Given the large differences in 
health care utilization between persons with dementia compared to those without dementia 
(including a large percentage of older adults with no hospitalizations or nursing home stays 
in a given year), this method of self-reported utilization provides valid estimates of the 
overall cost of dementia. However, it is less clear that self-reports of use are sufficiently 
accurate to allow comparisons between experimental groups of persons with Alzheimer's 
disease. Using data from an actual Alzheimer's disease clinical trial and a comprehensive 
database capturing health care utilization across the continuum of care, we demonstrate the 
magnitude of inaccuracy in self-reports. Caregivers tend to under-report use although errors 
in over-reporting also exist. We show that this bias in self-reports can substantially reduce 
statistical power in randomized trials and thereby increase the risk of a Type II error and 
these errors can also produce treatment effect bias that could produce inaccurate conclusions 
about the study results.
The use of self-reports rather than actual claims data is often justified through an argument 
that self-report data are less expensive to obtain. If the use of self-reports requires a larger 
sample size, however, self-report data may ultimately require a more expensive clinical trial. 
Most clinical trials to date have been powered based on outcomes such as cognition or 
behavior.16,17 These continuous variables, measured directly by the research team, often 
allow adequate statistical power at smaller sample sizes. Indeed, the typical Alzheimer's 
disease trial identified in recent systematic reviews had a sample size of less than 200 
subjects.6,33–35 In additional or secondary analyses, researchers may use self-report data 
collected during these trials to ascertain whether the intervention reduced health care use or 
costs or delayed institutionalization. In studies enrolling fewer than 350 subjects per group, 
utilization counts would have to drop more than the 20% simulated in the current study in 
order to demonstrate a statistically significant difference between groups. In cost 
effectiveness analyses, error in self-report may be further magnified because events are 
translated into average costs per event. Cost data are highly skewed with large numbers of 
persons with zero or near zero costs. Thus, in the setting of small sample sizes, one subject 
over- or under-reporting estimated high-cost events can have a substantial impact on the 
study conclusions. In addition, differential bias in self-reports, particularly in the timing of 
events such as nursing home use, could result from respondents' perceptions of social 
desirability. A differential bias in self-reports could occur, for example, in a study where the 
intervention cannot be double-blinded such as an intervention designed to delay 
institutionalization through caregiver education and support.
In 1999, we reported on the limitations of using self-report data to investigate health services 
use among a community-based sample of older adults.25 That study relied on a very 
different population that was a stratified random sample of 422 patients aged 60 and older 
who had visited the urban public health care system at least once in the previous 3 months. 
We completed a telephone to obtain subjects' self-reported health care use and compared 
these self-reports with data that were limited to local electronic medical records. Comparing 
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self-report data to the electronic record data, 24% of older adults with a hospitalization in 
the prior 12 months failed to report the episode and 28% of those with an emergency room 
visit failed to report the episode. Like the current study, self-reports of frequency of these 
services were substantially under-reported. In 2006, Bhandari and Wagner published a 
systematic review of 42 studies reporting on the accuracy of self-reported utilization data. 
The authors concluded that self-report data are of “variable accuracy” and that accuracy is 
affected by both telescoping and memory decay. Telescoping occurs when events are 
remembered to have occurred but respondents place the event in the wrong time period. The 
authors found that telescoping occurred regardless of the recall time frame and did not 
produce a consistent bias. The review also revealed that under-reporting was the most 
frequent problem and that under-reporting is made worse in the setting of increased health 
care use and older age. In the Bhandari and Wagner review, there were no studies that 
assessed the accuracy of proxy self-reports of health care use among older adults with 
dementia.
The term “under-reporting” can be viewed from different perspectives because the data are 
dominated by zero values and it is not necessary clear whether under-reporting one event in 
the context of one episode of care is more or less important than under-reporting one event 
in the context of many episodes of care. We have attempted to present and analyze the data 
in the manner most consistent with how the data are typically handled in a clinical trial and 
subsequent cost-effectiveness analyses. Extant studies rarely compare mean days of use for 
items like hospital, nursing home, or home health care because the distribution is severely 
skewed and dominated by zeros and this skewness is made more problematic by the 
relatively low number of enrolled subjects in a typical Alzheimer disease trial. The analyses 
in those studies, particularly for the nursing home outcomes which has been viewed as the 
most salient, is either “time to first use” or “any use”
The timing of nursing facility use has become an important metric for potential cost savings 
because delaying institutionalization by several months could amount to important cost 
savings. However, the results of our study suggest that proxy self-respondents may have 
difficulty in identifying an episode of nursing facility care and its precise timing or dates. 
Part of this difficulty may come from the vagaries inherent in terms such as “nursing home” 
and “institutionalization”. In the current environment in the United States, the same facility 
might provide for long-term care, subacute rehabilitation, hospice care, or respite care. We 
have previously documented the dynamic movement of patient with dementia from home to 
hospital to nursing home and back to home.11 Over the time period of this study, subjects 
could also have spent time in “hospital-based long-term care”, “long-term acute care 
facilities”, assisted living settings, and rehabilitation centers. Because the term “nursing 
home” connotes both permanent institutionalization and short-term rehabilitation and 
because similar care can be provided in any of these settings and the home, respondents 
could understandably be confused by these terms. It is unlikely that survey questions 
completed by lay respondents could keep abreast of the changing landscape of nursing 
facilities and their capabilities.
This study has limitations. First, these results may not generalize to nationally representative 
samples of older adults with dementia. This is a small sample from an urban public health 
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care system but the sample size is similar to the majority of prior clinical trials studying 
older adults with dementia. Second, although we have assembled a comprehensive database 
of health care use across the care continuum, we would not necessarily have identified 
private insurer pay or self-pay ambulatory care visits or hospitalizations. The database does 
capture private insurer pay or self-pay nursing facility use or home health care use. Third, 
the database we assembled is expensive and the cost of collecting such claims data may be 
greater than the cost of expanding a study's sample size.
We conclude that proxy self-reports of health care use appear to contain significant error and 
the magnitude of the error is sufficient to reduce statistical power and introduce bias into 
treatment effect results. Gathering actual utilization data or adjudicating proxy respondent's 
self-reports should be encouraged for those trials where utilization is a primary outcome.
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Figure 1. 
Estimated Power for an Equal-sized Two Group Comparison in Poisson Regression of a 
Count Outcome (assuming 20% reduction with loge(.7) under-reporting effect).
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Figure 2. 
Estimated Power for an Equal-sized Two Group Comparison in Poisson Regression of a 
Count Outcome (assuming 20% reduction with loge(.5) under-reporting effect).
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Table 1
Baseline characteristics of study sample (N=100)
Variable n (%) or mean (SD)
Patient characteristics
Female, n (%) 66 (66.0)
Black, n (%) 39 (39.0)
Married, n (%) 23 (23.0)
Medicaid recipient, n (%) 36 (39.6)
Age, mean (SD) 76.6 (6.3)
Annual income, mean (SD), $ 9,735.3 (6,965.3)
Education, mean (SD), years 7.8 (3.6)
MMSE score, mean (SD) 17.8 (5.3)
No of medications taking, mean (SD) 5.2 (2.7)
Chronic disease score, mean (SD) 6.8 (3.5)
Caregiver characteristics
Age, mean (SD) 54.4 (13.5)
Female, n (%) 85 (85.0)
Live with patient, n (%) 55 (55.0)
Relationship of caregiver to patient, n (%)
 Spouse 17 (17.0)
 Child 54 (54.0)
 Other 29 (29.0)
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Table 2
Agreement between actual use and self-reports based on any use vs. no use—cumulative use overtime, N=100
Site of care -6 -0 months -6-6 months -6–12 months -6–18 months
Emergency Department
 Any use in claims, n (%) 39 (39.0) 47 (47.0) 56 (56.0) 63 (63.0)
 Respondents reporting some use when none, n (%)* 17 (27.9) 19 (35.8) 19 (43.2) 19 (51.3)
 Respondents reporting no use when some, n (%)† 22 (56.4) 22 (46.8) 20 (35.7) 19 (30.2)
 Agreement between claims and self-report‡ 0.16 0.17 0.21 0.18
Hospital
 Any use in claims, n (%) 14 (14.0) 21 (21.0) 25 (25.0) 29 (29.0)
 Respondents reporting some use when none, n (%)* 10 (11.6) 12 (15.2) 16 (21.3) 14 (19.7)
 Respondents reporting no use when some, n (%)† 3 (21.4) 3 (14.3) 3 (12.0) 2 (06.9)
 Agreement between claims and self-report‡ 0.55 0.61 0.57 0.65
Home Health Care
 Any use in claims, n (%) 07 (7.0) 13 (13.0) 17 (17.0) 21 (21.0)
 Respondents reporting some use when none, n (%)* 9 (09.7) 8 (09.2) 11 (13.2) 12 (15.2)
 Respondents reporting no use when some, n (%)† 4 (57.1) 2 (15.4) 3 (17.6) 2 (09.5)
 Agreement between claims and self-report‡ 0.25 0.63 0.58 0.64
Nursing Home
 Any use in claims, n (%) 02 (2.0) 03 (3.0) 03 (3.0) 06 (6.0)
 Respondents reporting some use when none, n (%)* 6 (06.1) 8 (08.2) 11 (11.3) 8 (08.5)
 Respondents reporting no use when some, n (%)† 1 (50.0) 2 (66.6) 2 (66.6) 2 (33.3)
 Agreement between claims and self-report‡ 0.20 0.13 0.09 0.40
*percentage refers to the number of persons reporting some use divided by the number with no actual use;
†percentage refers to the number of persons reporting no use divided by the number with some actual use;
‡
Kappa statistic
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Table 3
Agreement between actual use and self-reports based on any use vs. no use—individual 6 month periods
Site of care -6 -0 months 0–6 months 6–12 months 12–18 months
N 100 89 80 68
Emergency Department
 Any use in claims, % 39 (39.0) 30 (33.7) 34 (42.5) 26 (38.2)
 Respondents reporting some use when none, %* 17 (27.9) 13 (22.0) 9 (19.6) 11 (26.2)
 Respondents reporting no use when some, %† 22 (56.4) 16 (53.3) 15 (44.1) 14 (53.9)
 Agreement between claims and self-report‡ 0.16 0.25 0.37 0.20
Hospital
 Any use in claims, % 14 (14.0) 10 (11.2) 8 (10) 8 (11.8)
 Respondents reporting some use when none, %* 10 (11.6) 8 (10.1) 9 (12.5) 5 (08.3)
 Respondents reporting no use when some, %† 3 (21.4) 5 (50.0) 3 (37.5) 1 (12.5)
 Agreement between claims and self-report‡ 0.55 0.35 0.38 0.65
Home Health Care
 Any use in claims, % 07 (7.0) 10 (11.2) 9 (11.3) 9 (13.2)
 Respondents reporting some use when none, %* 9 (09.7) 5 (06.3) 5 (07.0) 4 (06.8)
 Respondents reporting no use when some, %† 4 (57.1) 4 (40.0) 4 (44.4) 1 (11.1)
 Agreement between claims and self-report‡ 0.25 0.51 0.46 0.72
Nursing Home
 Any use in claims, % 02 (2.0) 01 (1.1) 00 (0.0) 3 (04.4)
 Respondents reporting some use when none, %* 6 (06.1) 2 (02.3) 3 (03.8) 0 (00.0)
 Respondents reporting no use when some, %† 1 (50.0) 1 (100.0) na 0 (00.0)
 Agreement between claims and self-report‡ 0.20 −0.02 na 1.00
na=not applicable
*percentage refers to the number of persons reporting some use divided by the number with no actual use; for example, reporting of ED visits when 
none -6-0 months 17/(100−39)=27.9%
†percentage refers to the number of persons reporting no use divided by the number with some actual use; for example, reporting no ED visits 
when some -6-0 months 22/39=27.9%
‡
Kappa statistic
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Table 4
Agreement between actual use and self-reports based on volume of use
Site of care 6 mo period – -6 to 0 months 12 mo period – -6 to 6 months
Emergency Department
 Correctly report zero use, n (%) 44 (44.0) 34 (34.0)
 Correctly report some use, n (%) 8 (8.0) 9 (9.0)
 Under-report volume of use, n (%) 29 (29.0) 31 (31.0)
 Over-report volume of use, (%) 19 (19.0) 26 (26.0)
 Agreement between claims and self-report* 0.14 0.14
Hospital
 Correctly report zero use, n (%) 76 (76.0) 67 (67.0)
 Correctly report some use, n (%) 7 (7.0) 12 (12.0)
 Under-report volume of use, n (%) 3 (3.0) 5 (5.0)
 Over-report volume of use, n (%) 14 (14.0) 16 (16.0)
Agreement between claims and self-report* 0.44 0.49
Home Health Care
 Correctly report zero use, n (%) 84 (84.0) 79 (79.0)
 Correctly report some use, n (%) 2 (2.0) 7 (7.0)
 Under-report volume of use, n (%) 5 (5.0) 4 (4.0)
 Over-report volume of use, n (%) 9 (9.0) 10 (10.0)
 Agreement between claims and self-report* 0.22 0.51
Nursing Home
 Correctly report zero use, n (%) 92 (92.0) 89 (89.0)
 Correctly report some use, n (%) 1 (1.0) 1 (1.0)
 Under-report volume of use, n (%) 1 (1.0) 2 (2.0)
 Over-report volume of use, n (%) 6 (6.0) 8 (8.0)
 Agreement between claims and self-report* 0.20 0.14
*
Kappa statistic
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